Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Differential Modulation of Transcription Factors and Cytoskeletal Proteins in Prostate Carcinoma Cells by a Bacterial Lactone.

Kumar SR, Bryan JN, Eaton AM, Robinson KL, Gajagowni S.

Biomed Res Int. 2018 May 9;2018:6430504. doi: 10.1155/2018/6430504. eCollection 2018.

2.

Immune response to C. novyi-NT immunotherapy.

DeClue AE, Axiak-Bechtel SM, Zhang Y, Saha S, Zhang L, Tung D, Bryan JN.

Vet Res. 2018 Apr 24;49(1):38. doi: 10.1186/s13567-018-0531-0.

3.

Identification of immunologic and clinical characteristics that predict inflammatory response to C. Novyi-NT bacteriolytic immunotherapy.

DeClue AE, Axiak-Bechtel SM, Zhang Y, Saha S, Zhang L, Tung DD, Bryan JN.

BMC Vet Res. 2018 Apr 2;14(1):119. doi: 10.1186/s12917-018-1424-1.

4.

Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin.

Henry CJ, Flesner BK, Bechtel SA, Bryan JN, Tate DJ, Selting KA, Lattimer JC, Bryan ME, Grubb L, Hausheer F.

J Vet Intern Med. 2018 Jan;32(1):370-376. doi: 10.1111/jvim.14848. Epub 2017 Oct 27.

5.

18 F-FDG-PET/CT as adjunctive diagnostic modalities in canine fever of unknown origin.

Grobman M, Cohn L, Knapp S, Bryan JN, Reinero C.

Vet Radiol Ultrasound. 2018 Jan;59(1):107-115. doi: 10.1111/vru.12562. Epub 2017 Sep 18.

PMID:
28925085
6.

Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.

Kumar SR, Bryan JN, Esebua M, Amos-Landgraf J, May TJ.

BMC Cancer. 2017 Feb 24;17(1):158. doi: 10.1186/s12885-017-3134-7.

7.

Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors.

Kumar SR, Kim DY, Henry CJ, Bryan JN, Robinson KL, Eaton AM.

Vet Comp Oncol. 2017 Dec;15(4):1527-1536. doi: 10.1111/vco.12297. Epub 2017 Jan 22.

PMID:
28111882
8.

The Current State of Clinical Application of Serum Biomarkers for Canine Lymphoma.

Bryan JN.

Front Vet Sci. 2016 Sep 30;3:87. eCollection 2016. Review.

9.

Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.

Tracy CJ, Whiting RE, Pearce JW, Williamson BG, Vansteenkiste DP, Gillespie LE, Castaner LJ, Bryan JN, Coates JR, Jensen CA, Katz ML.

Exp Eye Res. 2016 Nov;152:77-87. doi: 10.1016/j.exer.2016.09.003. Epub 2016 Sep 13.

10.

Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors.

Cai S, Zhang T, Forrest WC, Yang Q, Groer C, Mohr E, Aires DJ, Axiak-Bechtel SM, Flesner BK, Henry CJ, Selting KA, Tate D, Swarz JA, Bryan JN, Forrest ML.

Am J Vet Res. 2016 Sep;77(9):1005-16. doi: 10.2460/ajvr.77.9.1005.

11.

A One Health overview, facilitating advances in comparative medicine and translational research.

Stroud C, Dmitriev I, Kashentseva E, Bryan JN, Curiel DT, Rindt H, Reinero C, Henry CJ, Bergman PJ, Mason NJ, Gnanandarajah JS, Engiles JB, Gray F, Laughlin D, Gaurnier-Hausser A, Wallecha A, Huebner M, Paterson Y, O'Connor D, Treml LS, Stannard JP, Cook JL, Jacobs M, Wyckoff GJ, Likins L, Sabbagh U, Skaff A, Guloy AS, Hays HD, LeBlanc AK, Coates JR, Katz ML, Lyons LA, Johnson GC, Johnson GS, O'Brien DP, Duan D, Calvet JP, Gandolfi B, Baron DA, Weiss ML, Webster DA, Karanu FN, Robb EJ, Harman RJ.

Clin Transl Med. 2016 Aug;5(Suppl 1):26. doi: 10.1186/s40169-016-0107-4.

12.

Integrative veterinary medical education and consensus guidelines for an integrative veterinary medicine curriculum within veterinary colleges.

Memon MA, Shmalberg J, Adair HS 3rd, Allweiler S, Bryan JN, Cantwell S, Carr E, Chrisman C, Egger CM, Greene S, Haussler KK, Hershey B, Holyoak GR, Johnson M, Jeune SL, Looney A, McConnico RS, Medina C, Morton AJ, Munsterman A, Nie GJ, Park N, Parsons-Doherty M, Perdrizet JA, Peyton JL, Raditic D, Ramirez HP, Saik J, Robertson S, Sleeper M, Dyke JV, Wakshlag J.

Open Vet J. 2016;6(1):44-56. Epub 2016 Mar 28. Review.

13.

Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers: Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines.

Zhang T, Cai S, Groer C, Forrest WC, Yang Q, Mohr E, Douglas J, Aires D, Axiak-Bechtel SM, Selting KA, Swarz JA, Tate DJ, Bryan JN, Forrest ML.

J Pharm Sci. 2016 Jun;105(6):1891-1900. doi: 10.1016/j.xphs.2016.03.018. Epub 2016 May 4.

14.

Risk of Osteosarcoma in Dogs After Open Fracture Fixation.

Arthur EG, Arthur GL, Keeler MR, Bryan JN.

Vet Surg. 2016 Jan;45(1):30-5. doi: 10.1111/vsu.12416. Epub 2015 Nov 23.

PMID:
26595882
15.

Intravitreal Implantation of Genetically Modified Autologous Bone Marrow-Derived Stem Cells for Treating Retinal Disorders.

Tracy CJ, Sanders DN, Bryan JN, Jensen CA, Castaner LJ, Kirk MD, Katz ML.

Adv Exp Med Biol. 2016;854:571-7. doi: 10.1007/978-3-319-17121-0_76.

17.

Preclinical imaging and treatment of cancer: the use of animal models beyond rodents.

Axiak-Bechtel SM, Maitz CA, Selting KA, Bryan JN.

Q J Nucl Med Mol Imaging. 2015 Sep;59(3):303-16. Epub 2015 Jul 22. Review.

18.

Fetal Microchimerism in Cancer Protection and Promotion: Current Understanding in Dogs and the Implications for Human Health.

Bryan JN.

AAPS J. 2015 May;17(3):506-12. doi: 10.1208/s12248-015-9731-y. Epub 2015 Feb 19. Review.

19.

6-Thioguanine and zebularine down-regulate DNMT1 and globally demethylate canine malignant lymphoid cells.

Flesner BK, Kumar SR, Bryan JN.

BMC Vet Res. 2014 Dec 6;10:290. doi: 10.1186/s12917-014-0290-8.

20.

Gum arabic-coated radioactive gold nanoparticles cause no short-term local or systemic toxicity in the clinically relevant canine model of prostate cancer.

Axiak-Bechtel SM, Upendran A, Lattimer JC, Kelsey J, Cutler CS, Selting KA, Bryan JN, Henry CJ, Boote E, Tate DJ, Bryan ME, Katti KV, Kannan R.

Int J Nanomedicine. 2014 Oct 28;9:5001-11. doi: 10.2147/IJN.S67333. eCollection 2014.

Supplemental Content

Loading ...
Support Center